Delivery Order 75F40121D00018-75F40125F19004
Award Date
7/28/25
Potential Completion Date
8/6/30
Potential Value
$607K
Federal Agency
Food and Drug Administration
Awardee
We Pharma, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
Q999 - Medical- Other
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Takoma Park, MD 20901, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a firm-fixed price delivery order to We Pharma, Inc., doing business as WEP Clinical, to obtain a reliable source of currently marketed drug products to support FDA research studies for the Generic Drug User Fee Amendments (GDUFA) regulatory science program. The $477,943.82 order, which has no set-aside designation, is part of a larger 5-year, $9.5 million indefinite delivery contract awarded to We...
This is a delivery order awarded by the Food and Drug Administration (FDA) to We Pharma, Inc., a self-certified small disadvantaged business structured as a limited liability company. The contract, valued at $357,000.00, is for the provision of pharmaceutical drug products to support the FDA's various research, regulatory, and emergency response activities. We Pharma, doing business as WEP Clinical, holds two significant Indefinite Delivery Contracts (IDCs) with the FDA, totaling $9.5 million...
We Pharma, Inc. doing business as WEP Clinical has been awarded a firm fixed price delivery order valued at $2,000,000 by the Department of Health and Human Services' Food and Drug Administration (HHS FDA) to provide pharmaceutical products and services in support of FDA operations. This task order was issued against We Pharma's existing indefinite delivery contract with HHS FDA, valued at $6 million over five years, to supply drug products and emergency delivery services for FDA research and...
This is a firm-fixed-price delivery order awarded to We Pharma, Inc., a self-certified small disadvantaged business, by the Food and Drug Administration (FDA) under an Indefinite Delivery Contract (IDC). The purpose of this $399,561.18 award is to provide pharmaceutical drug products to support the FDA's research studies, regulatory activities, and emergency response needs. The contract has an ultimate completion date of August 6, 2024. This delivery order is not set-aside and is part of two...
We Pharma, Inc. doing business as WEP Clinical has been awarded a firm fixed price delivery order valued at one hundred thousand dollars from the Department of Health and Human Services' Food and Drug Administration (HHS FDA) to provide currently marketed drug products for FDA research studies. This order was issued against the company's existing five-year, nine and a half million dollar contract awarded in 2020 by HHS FDA to supply drug products for internal research in support of the...
This delivery order, awarded by the Department of Health and Human Services' Food and Drug Administration, is for $240,000 worth of pharmaceutical products to support domestic manufacturing and regulatory purposes. We Pharma, Inc. will provide the products in Takoma Park, Maryland by September 30, 2023 under a firm fixed price arrangement. As the FDA works to ensure the safety and effectiveness of drugs and medical devices, this contract will help the agency assess pharmaceutical manufacturing...
The Department of Health and Human Services Food and Drug Administration awarded a $169,918.01 firm fixed price delivery order contract to We Pharma, Inc. of Morrisville, North Carolina. The purpose of this requirement is to obtain currently marketed drug products for FDA research studies. We Pharma will provide the requested products to the FDA under this contract, which has a completion date of September 29, 2021. No set-aside designation was used for this award made on September 30, 2020.
The Department of Health and Human Services Food and Drug Administration awarded a $145,636.17 firm fixed price delivery order to We Pharma, Inc. of Silver Spring, Maryland for pharmaceutical products to support domestic manufacturing. No set-aside provisions were applied to this contract. We Pharma will provide the FDA's Office of Pharmaceutical Quality with domestic pharmaceutical manufacturing supplies through September 30th, 2022 at their Silver Spring location. As the regulatory body...
The Department of Health and Human Services Food and Drug Administration awarded a $250,000 firm fixed price delivery order contract to We Pharma, Inc. of Morrisville, North Carolina. The purpose of this requirement is to obtain currently marketed drug products for FDA research studies. Performance will take place in Morrisville, North Carolina through September 2021. No set-aside designation was applied to this award made under an unidentified contracting vehicle. The prime contractor will...
The Department of Health and Human Services Food and Drug Administration awarded a firm fixed-price purchase order to The Pharma Letter LIMITED, a for-profit organization, for a $113,008.00 pharmaceutical subscription for 25 users. The contract has a performance period ending May 20, 2025, with an award date of May 20, 2020. The subscription provides the FDA's Office of Global Policy and Strategy (OGPS) staff with access to global news, expert commentary, and analysis on pharmaceutical, generic,...